/CATX
CATX Stock - Perspective Therapeutics, Inc.
Healthcare|Medical - DevicesAMEX
$2.75+3.19%
+$0.09 (+3.19%) • Dec 19
69
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.38
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.71
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+281.8%upside
Target: $10.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CATX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.72 – $2.78
TARGET (TP)$10.50
STOP LOSS$2.53
RISK/REWARD1:35.2
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.24
52W High$5.39
52W Low$1.60
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | $1.43M | $7.10M | $10.79M | $10.05M |
| Gross Profit | N/A | $1.43M | $1.63M | $4.62M | $5.12M |
| Gross Margin | N/A | 100.0% | 23.0% | 42.8% | 50.9% |
| Operating Income | $10.46M | $-40,941,000 | $-15,182,000 | $-7,391,000 | $-3,437,000 |
| Net Income | $-79,279,000 | $-46,508,000 | $-14,670,000 | $-7,153,000 | $-3,188,000 |
| Net Margin | N/A | -3243.2% | -206.5% | -66.3% | -31.7% |
| EPS | $-1.23 | $-0.85 | $-0.27 | $-0.13 | $-0.06 |
Company Overview
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
8
89%
Hold / Neutral
1
11%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
8 Bullish1 Neutral/Bearish
Price Targets
$16
Average Target
↑ 489.9% Upside
Now
$5
Low
$16
Average
$25
High
Based on 9 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 24th 2025 | Truist | Resumed | Buy | $12 |
| October 10th 2025 | BTIG Research | Initiation | Buy | $14 |
| March 13th 2025 | H.C. Wainwright | Initiation | Buy | $10 |
| March 7th 2025 | Scotiabank | Initiation | Sector Outperform | $15 |
| November 25th 2024 | BofA Securities | Downgrade | Neutral | $5← $24 |
| October 24th 2024 | UBS | Initiation | Buy | $20 |
| October 1st 2024 | Wedbush | Initiation | Outperform | $25 |
| September 25th 2024 | Truist | Initiation | Buy | $21 |
| July 25th 2024 | BofA Securities | Initiation | Buy | $24 |
| May 9th 2024 | Cantor Fitzgerald | Initiation | Overweight | - |
Earnings History & Surprises
CATXBeat Rate
26%
Last 19 quarters
Avg Surprise
-20.5%
EPS vs Estimate
Beats / Misses
5/7
7 met exactly
Latest EPS
$-0.35
Q4 2025
EPS Surprise History
Q1 24
+50.0%
$-0.02vs$-0.04
Q2 24
+33.3%
$-0.20vs$-0.30
Q3 24
+19.0%
$-0.17vs$-0.21
Q4 24
0.0%
$-0.21vs$-0.21
Q1 25
+3.8%
$-0.25vs$-0.26
Q2 25
+10.7%
$-0.25vs$-0.28
Q3 25
0.0%
$-0.30vs$-0.30
Q4 25
-6.1%
$-0.35vs$-0.33
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 25, 2026 | $-0.38 | — | — | — |
Q4 2025 | Nov 10, 2025 | $-0.33 | $-0.35 | -6.1% | ✗ MISS |
Q3 2025 | Aug 13, 2025 | $-0.30 | $-0.30 | 0.0% | = MET |
Q2 2025 | May 12, 2025 | $-0.28 | $-0.25 | +10.7% | ✓ BEAT |
Q1 2025 | Mar 26, 2025 | $-0.26 | $-0.25 | +3.8% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-0.21 | $-0.21 | 0.0% | = MET |
Q3 2024 | Aug 12, 2024 | $-0.21 | $-0.17 | +19.0% | ✓ BEAT |
Q2 2024 | May 15, 2024 | $-0.30 | $-0.20 | +33.3% | ✓ BEAT |
Q1 2024 | Feb 15, 2024 | $-0.04 | $-0.02 | +50.0% | ✓ BEAT |
Q4 2023 | Nov 14, 2023 | $-0.40 | $-0.40 | 0.0% | = MET |
Q3 2023 | Aug 11, 2023 | $-0.30 | $-0.40 | -33.3% | ✗ MISS |
Q2 2023 | May 15, 2023 | $-0.01 | $-0.01 | 0.0% | = MET |
Q1 2023 | Feb 16, 2023 | $-0.01 | $-0.02 | -100.0% | ✗ MISS |
Q4 2022 | Nov 14, 2022 | $-0.01 | $-0.03 | -200.0% | ✗ MISS |
Q3 2022 | Sep 28, 2022 | $-0.01 | $-0.01 | 0.0% | = MET |
Q2 2022 | May 10, 2022 | $-0.01 | $-0.01 | -33.3% | ✗ MISS |
Q1 2022 | Feb 8, 2022 | $-0.01 | $-0.01 | -33.3% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $-0.01 | $-0.02 | -100.0% | ✗ MISS |
Q3 2021 | Sep 21, 2021 | $-0.01 | $-0.01 | 0.0% | = MET |
Q2 2021 | May 13, 2021 | $-0.01 | $-0.01 | 0.0% | = MET |
Latest News
Perspective Therapeutics to Showcase New Cancer Treatment Data at Major Medical Conference
📈 PositiveBenzinga•Dec 4, 2025, 12:05 PM
Truist Securities Assumes Perspective Therapeutics at Buy, Raises Price Target to $12
📈 PositiveBenzinga•Nov 24, 2025, 06:15 PM
UBS Maintains Buy on Perspective Therapeutics, Lowers Price Target to $7
➖ NeutralBenzinga•Nov 21, 2025, 04:16 PM•Also:
B. Riley Securities Maintains Buy on Perspective Therapeutics, Lowers Price Target to $11
➖ NeutralBenzinga•Nov 18, 2025, 04:57 PM
Perspective Therapeutics Q3 EPS $(0.35) Misses $(0.33) Estimate, Sales $209.000K Miss $223.833K Estimate
📉 NegativeBenzinga•Nov 10, 2025, 09:06 PM
Perspective Therapeutics shares are trading lower. The company announced interim results from from its ongoing Phase 1/2a clinical trial of [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor type 2 expressing neuroendocrine tumors were presented at the European Society for Medical Oncology.
➖ NeutralBenzinga•Oct 20, 2025, 03:42 PM
Perspective Therapeutics Reports 44% Confirmed Response Rate And 87.5% Progression-Free Patients Treated With [212Pb]VMT-α-NET At ESMO Congress 2025
📈 PositiveBenzinga•Oct 20, 2025, 08:34 AM
BTIG Reiterates Buy on Perspective Therapeutics, Maintains $14 Price Target
📈 PositiveBenzinga•Oct 13, 2025, 01:57 PM
Perspective Therapeutics shares are trading higher after BTIG initiated coverage on the stock with a Buy rating and announced a price target of $14.
📈 PositiveBenzinga•Oct 10, 2025, 03:15 PM
BTIG Initiates Coverage On Perspective Therapeutics with Buy Rating, Announces Price Target of $14
📈 PositiveBenzinga•Oct 10, 2025, 10:26 AM
HC Wainwright & Co. Reiterates Buy on Perspective Therapeutics, Maintains $10 Price Target
📈 PositiveBenzinga•Oct 3, 2025, 11:33 AM
Perspective Therapeutics Announces First Patient Treated With PSV359 In Second Cohort Of Phase 1/2a Dose-Finding Trial To Determine Safety And Preliminary Anti-Tumor Activity
📈 PositiveBenzinga•Oct 2, 2025, 11:03 AM
HC Wainwright & Co. Reiterates Buy on Perspective Therapeutics, Maintains $10 Price Target
📈 PositiveBenzinga•Sep 19, 2025, 11:32 AM
Perspective Therapeutics Says First Patient Dosed In New Cohort Of Phase 1/2a Trial Evaluating The Safety Of [212Pb]VMT01
📈 PositiveBenzinga•Sep 15, 2025, 11:08 AM
Perspective Therapeutics Names Joel Sendek CFO As Juan Graham Departs
➖ NeutralBenzinga•Sep 4, 2025, 11:24 AM
Perspective Therapeutics Reports Q2 Loss
📉 NegativeThe Motley Fool•Aug 13, 2025, 10:59 AM
Frequently Asked Questions about CATX
What is CATX's current stock price?
Perspective Therapeutics, Inc. (CATX) is currently trading at $2.75 per share. The stock has moved +3.19% today.
What is the analyst price target for CATX?
The average analyst price target for CATX is $10.50, based on 1 analyst.
What sector is Perspective Therapeutics, Inc. in?
Perspective Therapeutics, Inc. operates in the Healthcare sector, specifically within the Medical - Devices industry. The company is traded on the AMEX exchange.
What is CATX's market cap?
Perspective Therapeutics, Inc. has a market capitalization of $0.20 billion, making it a small-cap company.
Does CATX pay dividends?
No, Perspective Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAVR
Anteris Technologies Global Corp.
$4.94
Mkt Cap: $0.2B
ELMD
Electromed, Inc.
$28.62
Mkt Cap: $0.2B
HSDT
Solana Company
$2.98
Mkt Cap: $0.1B
IVVD
Invivyd, Inc.
$2.30
Mkt Cap: $0.3B
MXCT
MaxCyte, Inc.
$1.50
Mkt Cap: $0.2B
NNOX
Nano-X Imaging Ltd.
$2.99
Mkt Cap: $0.2B
NYXH
Nyxoah S.A.
$4.85
Mkt Cap: $0.2B
PROF
Profound Medical Corp.
$7.63
Mkt Cap: $0.2B
STIM
Neuronetics, Inc.
$1.40
Mkt Cap: $0.1B
TLSI
TriSalus Life Sciences, Inc.
$7.42
Mkt Cap: $0.2B
Explore stocks similar to CATX for comparison